Holen Sie sich die Stockscreener-App
11.02
0.27%
0.03
Handel nachbörslich:
11.02
Keros Therapeutics Inc Aktie (KROS) Neueste Nachrichten
Myelofibrosis Market: Strong Pharma Growth Forecast Through 2034 – DelveInsight | Lynk Pharma, Samus Therapeutics, Taiga Biotech, Bristol-Myers Squibb, Sumitomo Pharma Oncology, Keros Therapeutics - Barchart.com
Technical Reactions to KROS Trends in Macro Strategies - Stock Traders Daily
Keros Therapeutics Partners with Healey & AMG Center for ALS to Launch Phase 2 Trial of Rinvatercept for ALS Treatment - Minichart
Keros Therapeutics Advances Rinvatercept in ALS Collaboration - TipRanks
Keros Therapeutics Presents Additional Clinical Data from Its Rinvatercept Program at the 2026 MDA Clinical & Scientific Conference - Bitget
Keros Therapeutics Announces Collaboration with Sean M. Healey & AMG Center for ALS - The Manila Times
Keros Therapeutics to Test Rinvatercept in Phase 2 ALS Trial with Mass General; Phase 1 Data Presented - TradingView
Personalized ALS trial to test Keros rinvatercept at Mass General - Stock Titan
Q1 EPS Estimate for Keros Therapeutics Decreased by Analyst - MarketBeat
Sell Signal: Does Keros Therapeutics Inc stock reflect fundamentals2025 Top Gainers & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Can Keros Therapeutics Rinvatercept Stand Out in the DMD Market? - The Globe and Mail
Keros Therapeutics (NASDAQ:KROS) Stock Rating Lowered by Wall Street Zen - MarketBeat
Is Keros Therapeutics Inc vulnerable to short sellers2025 Price Targets & Weekly Sector Rotation Insights - baoquankhu1.vn
Can Keros Therapeutics Inc be the next market leaderM&A Rumor & Daily Technical Stock Forecast Reports - baoquankhu1.vn
Is Keros Therapeutics Inc. stock a buy before product launchesPortfolio Value Summary & Growth Focused Stock Reports - Naître et grandir
Investment Review: Is now the right time to enter Keros Therapeutics IncChart Signals & Precise Swing Trade Entry Alerts - baoquankhu1.vn
Can Keros Therapeutics' Rinvatercept Distinguish Itself in the DMD Marketplace? - Bitget
What is HC Wainwright's Estimate for KROS FY2030 Earnings? - MarketBeat
Keros Therapeutics’ Smaller Reporting Status Cuts Disclosure Burden but May Weigh on Investor Appeal and Volatility - TipRanks
Wells Fargo & Company Cuts Keros Therapeutics (NASDAQ:KROS) Price Target to $20.00 - MarketBeat
Wells Fargo Maintains "Overweight" on Keros Therapeutics (KROS), Lowers Price Target | KROS Stock News - GuruFocus
Keros Therapeutics Reports FY25 Results, Highlights Progress Across Hematology And Muscle Pipeline - Nasdaq
Keros Therapeutics, Inc. (KROS) Reports Q4 Loss, Misses Revenue Estimates - Bitget
Keros Therapeutics (NASDAQ: KROS) lands $200M Takeda deal and advances TGF-ß pipeline - Stock Titan
Keros Therapeutics (NASDAQ: KROS) swings to 2025 profit on Takeda license windfall - Stock Titan
Keros Highlights Rinvatercept Strategy in Updated Investor Presentation - TipRanks
Keros Therapeutics (NASDAQ:KROS) Releases Earnings Results, Misses Estimates By $0.37 EPS - MarketBeat
Keros Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results - GlobeNewswire
KROS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
ADAR1 Issues Open Letter to Keros Board, Encouraging Constructive Dialogue on Strategy, Capital Allocation, and Board Renewal - Intellectia AI
Keros Therapeutics Touts Rinvatercept DMD Trial Start, Eyes ALS Phase II Talks at Oppenheimer Conference - MarketBeat
Trading the Move, Not the Narrative: (KROS) Edition - Stock Traders Daily
Keros Therapeutics, Inc. (KROS) Investor Outlook: Exploring The 53% Potential Upside - DirectorsTalk Interviews
Keros Therapeutics, Inc. $KROS is Western Standard LLC's Largest Position - MarketBeat
Keros Therapeutics adds former Lyell CFO to board By Investing.com - Investing.com India
Keros Therapeutics Adds Veteran Finance Leader to Board - TipRanks
Keros Therapeutics adds former Lyell CFO to board - Investing.com
Keros Therapeutics (KROS) CEO awarded 317,000 stock options with vesting hurdles - Stock Titan
Keros Therapeutics (KROS) CFO receives 60,000-share stock option grant - Stock Titan
Keros Therapeutics (KROS) awards Chief Legal Officer 80,000 options - Stock Titan
Keros Therapeutics (NASDAQ: KROS) grants CSO 75,000 options - Stock Titan
Keros Therapeutics Appoints Charles Newton to its Board of Directors - GlobeNewswire
KROS Technical Analysis & ETF Price Forecast - Intellectia AI
Keros Therapeutics, Inc. (KROS) Investor Outlook: Analyzing a 38.97% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Keros Therapeutics (KROS) CEO auto-sells 7,015 shares for tax withholding - Stock Titan
Can Keros Therapeutics Inc. reach resistance levels soonJuly 2025 Outlook & Verified Swing Trading Watchlists - mfd.ru
Risk Hedge: What is the next catalyst for Keros Therapeutics IncQuarterly Portfolio Report & Long-Term Safe Investment Ideas - baoquankhu1.vn
Portfolio Update: Is now the right time to enter Keros Therapeutics IncJuly 2025 Movers & Low Risk Growth Stock Ideas - baoquankhu1.vn
Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences - The Manila Times
Keros Therapeutics CEO to Present at Multiple Conferences - TipRanks
Keros Therapeutics CEO to Present at Oppenheimer, TD Cowen and Leerink Conferences - TradingView
Keros Therapeutics (NASDAQ: KROS) lines up CEO talks at key conferences - Stock Titan
Sentiment Recap: Can Keros Therapeutics Inc weather a recessionQuarterly Trade Review & Weekly Stock Performance Updates - baoquankhu1.vn
Should Investors Buy, Sell or Hold KROS Stock Ahead of Q4 Earnings? - TradingView
Keros Therapeutics (KROS) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
Tang Capital reports 0% stake in Keros Therapeutics (NASDAQ: KROS) - Stock Titan
D. E. Shaw group discloses 3.9% Keros Therapeutics (KROS) ownership in 13G/A - Stock Titan
Keros Therapeutics, Inc. (NASDAQ:KROS) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):